Latest KRAS Stories
Company's liquid biopsy technology features single molecule sensitivity and the ability to obtain significantly more circulating tumor DNA (ctDNA) from urine samples vs.
Two innovative medical technology companies, InSilico Medicine, Inc.
Important Step Towards Increasing Treatment Options for Patients With This Serious Disease THOUSAND OAKS, Calif., April 6, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the
Advancing Its Precision Cancer Monitoring Platform Using Liquid Biopsy to Improve the Standard of Cancer Care SAN DIEGO, March 12, 2015 /PRNewswire/ -- Trovagene, Inc.
DALLAS, March 2, 2015 /PRNewswire/ -- ReportsnReports.com adds Lonsurf and Avastin (Colorectal Cancer) - Forecast and Market Analysis to 2023 research report focuses on
THOUSAND OAKS, Calif., Feb.
Prospective clinical studies to evaluate Trovagene's Precision Cancer Monitoring platform to determine the emergence of resistance mutations using circulating tumor DNA SAN DIEGO,
Trovagene's proprietary KRAS assay enables physicians to determine mutational status, monitor treatment response, and use genomics to aid in predicting patient prognosis SAN DIEGO,
Exploratory Analysis of Phase 2 Trial Shows Earlier and Sustained Responses in Patients Treated With Vectibix Versus Bevacizumab THOUSAND OAKS, Calif., Jan.
MANHATTAN BEACH, Calif., Jan.
- A serpent whose bite was fabled to produce intense thirst.